Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04072887 · ClinicalTrials.gov registry record · Phase 2

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
974
Enrollment target
20
Study locations

NCT04072887 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 974 participants, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04072887, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
974 participants
Enrollment target
20
Study locations

Study Summary

This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple inhaled therapy of LABA, LAMA and ICS.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Placebo
  • DRUG QBW251
  • DRUG COPD maintenance background therapy

Study Locations (20)

Florida

  • Novartis Investigative Site - Ormond Beach
  • Novartis Investigative Site - Sarasota
  • Novartis Investigative Site - Winter Park

Louisiana

  • Novartis Investigative Site - Crowley
  • Novartis Investigative Site - New Orleans
  • Novartis Investigative Site - Zachary

North Carolina

  • Novartis Investigative Site - Charlotte
  • Novartis Investigative Site - Gastonia
  • Novartis Investigative Site - Shelby

California

  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Westminster

Minnesota

  • Novartis Investigative Site - Edina
  • Novartis Investigative Site - Minneapolis

Missouri

  • Novartis Investigative Site - Saint Charles
  • Novartis Investigative Site - St Louis

Alabama

  • Novartis Investigative Site - Andalusia

Kentucky

  • Novartis Investigative Site - Florence

Trial Details

FieldValue
Enrollment Target 974 participants
Start Date 2019-09-12
Est. Completion 2022-02-01
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04072887

The ClinicalTrials.gov registry entry for NCT04072887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 974 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04072887 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Louisiana, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04072887 about?

NCT04072887 is a clinical study titled "Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients". This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple i...

What is the current status of trial NCT04072887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 974 participants. The study started on 2019-09-12. Estimated completion is 2022-02-01.

What conditions does trial NCT04072887 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT04072887?

The interventions under investigation include: Placebo (DRUG), QBW251 (DRUG), COPD maintenance background therapy (DRUG).

Who is sponsoring clinical trial NCT04072887?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04072887 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.